ARCHIVES

Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.

This article is from The Cancer Letter archive.

Vol. 30 No. 28 | July 9, 2004

Download PDF Visit The Full Archive

Related Articles

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

Stone(y) Silence Didn’t Save His Job; Niamd’s Rall Rumored as Top Choice As New NIH Director

December 20, 1974

NIH Deputy Director Ruth Kirschstein Plans Transition To Senior Advisor

October 4, 2002

Arbuck Leaves NCI to Guide BMS Oncology Pipeline.

September 7, 2001

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

November 8, 2002

NCI RFA: Basic Biobehavioral Research

August 6, 1999